The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
本发明涉及新化合物,以及用于它们制备的方法,它们在治疗中的应用以及包含这些新化合物的药物组合物。
FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS
申请人:AstraZeneca AB
公开号:EP2027129A2
公开(公告)日:2009-02-25
[EN] MGLUR5 MODULATORS V<br/>[FR] MODULATEURS MGLUR5 V
申请人:ASTRAZENECA AB
公开号:WO2007130824A2
公开(公告)日:2007-11-15
[EN] The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds. [FR] L'invention concerne de nouveaux composés, un procédé de préparation de ces derniers, leur utilisation en thérapie et des compositions pharmaceutiques renfermant les nouveaux composés précités.
[EN] AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5<br/>[FR] DÉRIVÉS D'AMINO1,2,4-TRIAZOLES EN TANT QUE MODULATEURS DU MGLUR5
申请人:ASTRAZENECA AB
公开号:WO2009054794A1
公开(公告)日:2009-04-30
The present invention relates to new amino 1,2,4-triazole compounds, process for their preparation, pharmaceutical compositions containing said compounds an their use in therapy. The compounds act as modulators of metabotropic glutamate receptors (mGluR) and thus useful in the treatment of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease, pain, anxiety and irritable bowel syndrome.
AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5
申请人:ISAAC Methvin
公开号:US20090111821A1
公开(公告)日:2009-04-30
The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.